• 1
    Gidding CEM, Kellie SJ, Kamps WA, de Graaf SSN. Vincristine revisited. Crit Rev Oncol Hematol. 1999; 29: 267287.
  • 2
    Ghosh K, Sivakumaran M, Murphy P, Chapman CS, Wood JK. Visual hallucinations following treatment with vincristine. Clin Lab Haematol. 1996; 16: 355357.
  • 3
    Calabresi P, Parkes RE. Chemotherapy of neoplastic diseases. In: GilmanAG, GoodmanLS, HallTW, MuradF, editors. The pharmacological basis of therapeutics. 7th edition. New York: McMillan, 1985: 12771280.
  • 4
    Laurens A, Larroque P, Laurent G. Neuropsychiatric toxicity of vincristine sulphate therapy. Clin Haematol. 1976; 4: 137139.
  • 5
    Jackson DV, Bender RA. The clinical pharmacology of the vinca alkaloids, epipodophyllotoxins and maytansine. In: PinedoH, editor. Clinical pharmacology of anti-neoplastic drugs. New York: Elsevier-North Holland Publishing, 1978: 277294.
  • 6
    Stewart DJ. A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors. J Neuro-Oncol. 1994; 20: 121139.
  • 7
    Boucher Y, Baxter LT, Jain RK. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res. 1990; 50: 44784484.
  • 8
    Hughes CS, Vaden SL, Manaugh CA, Price GS, Hudson LC. Modulation of doxorubicin concentration by cyclosporin A in brain and testicular barrier tissues expressing P-glycoprotein in rats. J Neuro-Oncol. 1998; 37: 4554.
  • 9
    Schumacher U, Mollgard K. The multidrug-resistance P-glycoprotein (Pgp, MDR1) is an early marker of blood-brain barrier development in the microvessels of the developing human brain. Histochem Cell Biol. 1997; 108: 179182.
  • 10
    Neuwelt EA, Frenkel EP, Diehl J, Vu LH. Reversible osmotic blood-brain barrier disruption in humans: implications for the chemotherapy of malignant brain tumors. Neurosurgery. 1980; 7: 4452.
  • 11
    Waters K. Australian and New Zealand trials of acute lymphoblastic leukemia of childhood. Intl J Pediatr Hematol Oncol. 1998; 5: 187197.
  • 12
    Morland BJ, Shaw PJ. Induction toxicity of a modified Memorial Sloan-Kettering New York II protocol in children with relapsed acute lymphoblastic leukemia: a single institution study. Med Pediatr Oncol. 1996; 27: 139144.
  • 13
    Bloemhof H, Van Dijk KN, de Graaf SSN, Vendrig DE, Uges DRA. Sensitive method for the determination of vincristine in human serum by high-performance liquid chromatography after on-line column-extraction. J Chromatogr. 1991; 572: 171179.
  • 14
    Crom WR, de Graaf SSN, Synold T, et al. Pharmacokinetics of vincristine in children and adolescents with acute lymphoblastic leukemia. J Pediatr. 1994; 125: 642649.
  • 15
    de Graaf SSN, Bloemhof H, Vendrig DE, Uges DRA. Vincristine disposition in children with acute lymphoblastic leukemia. Med Pediatr Oncol. 1995; 24: 235240.
  • 16
    Jackson DV, Sethi VS, Spurr CL, McWhorter JM. Pharmacokinetics of vincristine in the cerebrospinal fluid of humans. Cancer Res. 1981; 41: 14661468.
  • 17
    Sethi VS, Burton SS, Jackson DV. A sensitive radioimmunoassay for vincristine and vinblastine. Cancer Chemother Pharmacol. 1980; 4: 183187.
  • 18
    Jordan MA, Thrower D, Wilson L. Mechanism of inhibition of cell proliferation by vinca alkaloids. Cancer Res. 1991; 51: 22122222.
  • 19
    Jackson DV, Bender RA. Cytotoxic thresholds of vincristine in a murine and a human leukemia cell line in vitro. Cancer Res. 1979; 39: 43464349.
  • 20
    Singh A, Belshe BD, Gumerlock MK. Radionuclide assessment of blood-brain barrier disruption performed for chemotherapy of high-grade gliomas. Intl J Radiat App Instrum. 1991; 18: 641645.
  • 21
    Duffner PK, Horowitz ME, Krischer JP, et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med. 1993; 328: 17251731.
  • 22
    Geyer JR, Zeltzer PM, Boyett JM, et al. Survival of infants with primitive neuroectodermal tumors or malignant ependymomas of the CNS treated with eight drugs in 1 day: a report from the Children's Cancer Group. J Clin Oncol. 1994; 12: 16071615.
  • 23
    Packer RJ, Ater J, Allen J, et al. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg. 1997; 86: 747754.
  • 24
    Horton JK, Houghton PJ, Houghton JA. Relationships between tumor responsiveness, vincristine pharmacokinetics and arrest of mitosis in human tumor xenografts. Biochem Pharmacol. 1988; 37: 39954000.
  • 25
    Gajjar A, Heideman RL, Kovnar EH, et al. Response of pediatric low grade gliomas to chemotherapy. Pediatr Neurosurg. 1993; 19: 113120.
  • 26
    Smart CR, Ottoman RE, Rochlin DB, Hornes J, Silva AR, Goepfert H. Clinical experience with vincristine (NSC-67574) in tumors of the central nervous system and other malignant diseases (Part 1). Cancer Chemother Rep. 1968; 52: 733741.
  • 27
    Lampkin B, Mauer AM, McBride BH. Response of medulloblastoma to vincristine sulphate: a case report. Pediatrics. 1967; 39: 761763.
  • 28
    Lassman LP, Pearce GW, Banna M, Jones RD. Vincristine sulphate in the treatment of skeletal metastases from cerebellar medulloblastoma. J Neurosurg. 1969; 30: 4249.
  • 29
    Lassman LP, Pearce GW, Gang J. Effect of vincristine sulphate on the intracranial gliomata of childhood. Br J Surg. 1966; 53: 774777.
  • 30
    Crist WM Ragab AH, Vietti TJ, Ducos R, Chu JY. Chemotherapy of childhood medulloblastoma. Am J Dis Child. 1976; 130: 639642.
  • 31
    Rosenstock JG, Evans AE, Schut L. Response to vincristine of recurrent brain tumors in children. J Neurosurg. 1976; 45: 135140.
  • 32
    Thyss A, Milano G, Deville A, Manassero J, Renee N, Schneider M. Effect of dose and repeat intravenous 24 hour infusions of methotrexate on cerebrospinal fluid availability in children with hematological malignancies. Eur J Cancer Clin Oncol. 1987; 23: 843847.
  • 33
    Slevin ML, Piall EM, Aherne GW, Harvey VJ, Johnston A, Lister TA. Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid. J Clin Oncol. 1983; 1: 546551.
  • 34
    Handke KR, Wedlund PJ, Noone RM, Wilkinson GR, Greco FA, Wolff SN. Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients. Cancer Res. 1984; 44: 379382.
  • 35
    Balis FM, Poplack DG. Central nervous system pharmacology of antileukemic drugs. Am J Pediatr Hematol/Oncol. 1989; 11: 7486.
  • 36
    Heideman RL, Cole DE, Balis F, Sato J, Reaman GH, Packer RJ. Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose dependent plasma clearance of thiotepa. Cancer Res. 1989; 49: 736741.
  • 37
    DeGregorio MW, King OY, Holleran WM, et al. Ultrafiltrate and total platinum in plasma and cerebrospinal fluid in a patient with neuroblastoma. Cancer Treat Rep. 1985; 69: 14411442.